Table 2 Clinical trials of targeting HSP90 ATPase inhibitors
From: Advances in the structures, mechanisms and targeting of molecular chaperones
Name | Adjunctive agents | Conditions | Phase | Status | First Posted | NCT number |
|---|---|---|---|---|---|---|
17-AAG | / | ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia | I | Terminated | 2005 | NCT00319930 |
/ | Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma | II | Completed | 2005 | NCT00117988 | |
/ | Advanced Solid Tumors or Non-Hodgkin’s Lymphoma | I | Terminated | 2003 | NCT00019708 | |
/ | Relapsed or Refractory Solid Tumors or Leukemia | I | Completed | 2004 | NCT00079404 | |
Sorafenib tosylate | Unresectable or Metastatic Solid Tumors | I | Completed | 2005 | NCT00121264 | |
17-DMAG | / | HER2 Positive Breast Cancer | II | Terminated | 2008 | NCT00780000 |
/ | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Prolymphocytic Leukemia | I | Terminated | 2010 | NCT01126502 | |
Trastuzumab and Paclitaxel | Breast Cancer or Solid Tumor | I | Completed | 2008 | NCT00803556 | |
IPI-504 | / | Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer, | II | Terminated | 2010 | NCT01228435 |
Docetaxel | Non-small Cell Lung Cancer | II | Completed | 2011 | NCT01362400 | |
IPI-493 | / | Hematologic Malignancies | I | Terminated | 2010 | NCT01193491 |
/ | Advanced Malignancies | I | Terminated | 2008 | NCT00724425 | |
AT13387 | / | Solid Tumors, Breast Cancer | I | Completed | 2010 | NCT01246102 |
/ | Metastatic Solid Tumors | I | Completed | 2009 | NCT00878423 | |
Crizotinib | Non-Small Cell Lung Cancer | I/II | Completed | 2012 | NCT01712217 | |
Abiraterone Acetate | Prostate Cancer | I/II | Completed | 2012 | NCT01685268 | |
STA-9090 | / | Solid Tumors | I | Completed | 2008 | NCT00687934 |
Docetaxel | Solid Tumor Malignancies | I | Completed | 2010 | NCT01183364 | |
BIIB021 | / | Gastrointestinal Stromal Tumors | II | Completed | 2008 | NCT00618319 |
/ | Advanced Solid Tumors | I | Completed | 2008 | NCT00618735 | |
Antacid | Advanced Solid Tumors | I | Completed | 2009 | NCT01017198 | |
Exemestane | Hormone Receptor Positive Metastatic Breast Cancer | II | Completed | 2009 | NCT01004081 | |
BIIB028 | / | Advanced Solid Tumors | I | Completed | 2008 | NCT00725933 |
PU-H71 | / | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | I | Terminated | 2019 | NCT03935555 |
/ | Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma | I | Terminated | 2012 | NCT01581541 | |
/ | PET Imaging of Cancer Patients | Early I | Active, not recruiting | 2011 | NCT01269593 | |
MPC-3100 | / | Refractory or Relapsed Cancer | I | Completed | 2009 | NCT00920205 |
Debio 0932 | / | Cancer, Neoplasms, Solid Tumors, Lymphoma | I | Completed | 2010 | NCT01168752 |
/ | Psoriasis Vulgaris | I | Unknown | 2018 | NCT03675542 | |
XL888 | / | Solid Tumors | I | Terminated | 2008 | NCT00796484 |
Vemurafenib | Melanoma | I | Completed | 2012 | NCT01657591 | |
Vemurafenib and Cobimetinib | Melanoma | I | Active, not recruiting | 2016 | NCT02721459 | |
SNX-5422 | / | Solid Tumor Malignancy, Lymphoid Malignancy, Leukemia, Lymphoma | I | Completed | 2008 | NCT00647764 |
/ | Solid Tumor Malignancies | I | Completed | 2007 | NCT00506805 | |
/ | HER2 Positive Cancers. | I/II | Terminated | 2013 | NCT01848756 | |
Ibrutinib | Chronic lymphocytic leukemia | I | Withdraw | 2016 | NCT02914327 | |
TAS-116 | Palbociclib | Breast and Rb-null Cancer | I | Recruiting | 2022 | NCT05655598 |
Imatinib and Sunitinib | Gastrointestinal Stromal Tumors | I | Recruiting | 2022 | NCT05245968 | |
/ | Solid Tumors | I | Completed | 2016 | NCT02965885 | |
HSP990 | / | Advanced Solid Tumors | I | Terminated | 2010 | NCT01064089 |
/ | Advanced Solid Tumors | I | Completed | 2009 | NCT00879905 |
